Why this trial matters
Most NMN human trials have been small, 20 to 80 participants, and focused on physical endpoints like grip strength, walking speed, and insulin sensitivity. The largest randomized, double-blind, placebo-controlled trial of NMN to date shifted the primary endpoint to cognitive function, and reported a significant improvement.
Cognitive aging is the endpoint consumers actually fear. A supplement that demonstrably improves cognitive markers in a rigorous trial would represent a category shift for NMN, which has been sold on the basis of NAD+ elevation data and animal lifespan studies.
The largest NMN RCT to date reported significant cognitive improvement. Prior trials measured grip strength and walking speed.
What we know and what we don't
The results were reported via a secondary source before peer-reviewed publication. The effect size, p-value, dose, and duration were not specified in the source material at time of writing. This matters because a "significant improvement" in a large trial could mean a large, clinically meaningful effect or a small, statistically detectable effect.
Until the peer-reviewed publication confirms the details, treat this as a promising signal, not a confirmed result. The history of longevity supplements is full of promising signals that shrank or disappeared under scrutiny.
The Nestle study that arrived alongside it
A Nestle Health Science-led study found that 14-day supplementation of NR and NMN combined altered metabolic health markers in ways not previously described. This is industry-funded and not yet peer-reviewed. Nestle Health Science sells NAD+ products, which is a conflict of interest to consider.
The 14-day duration is too short to draw conclusions about sustained effects. But the metabolic pathway changes suggest NAD+ precursors may do something beyond simply raising blood NAD+ levels, which is the only thing most consumers currently measure.
NAD+ and Alzheimer's
Early-phase clinical trials of NAD+ precursors in Alzheimer's patients have reported improvements in memory, physical movement, and metabolic health. These are small, early-stage trials and should not be interpreted as evidence that NAD+ supplements treat or prevent Alzheimer's. The mechanism is plausible: NAD+ depletion in the brain during aging impairs mitochondrial function and DNA repair. But plausibility is not proof.
What to watch
- Peer-reviewed publication of the large NMN cognitive trial with effect sizes and p-values.
- Replication in an independent cohort, since a single trial, however large, is not confirmation.
- Dose-response data, because the optimal NMN dose for cognitive effects may differ from the dose for physical performance.
- Long-term safety data, since cognitive aging is measured over decades, not weeks.